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Cannabinoid-based medicines have therapeutic potential for the treatment of pain. Augmentation of levels of endocannabinoids with
inhibitors of fatty acid amide hydrolase (FAAH) is analgesic in models of acute and inflammatory pain states. The aim of this study was
to determine whether local inhibition of FAAH alters nociceptive responses of spinal neurons in the spinal nerve ligation model of
neuropathic pain. Electrophysiological studies were performed 14–18 d after spinal nerve ligation or sham surgery, and the effects of the
FAAH inhibitor cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester (URB597) onmechanically evoked responses of spinal neurons
and levels of endocannabinoids were determined.
Intraplantar URB597 (25 g in 50 l) significantly ( p  0.01) attenuated mechanically evoked responses of spinal neurons in
sham-operated rats. Effects of URB597 were blocked by the cannabinoid 1 receptor (CB1) antagonist AM251 [N-1-(2,4-dichlorophenyl)-
5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] (30g in 50l) and the opioid receptor antagonist naloxone.
URB597 treatment increased levels of anandamide, 2-arachidonyl glycerol, and oleoyl ethanolamide in the ipsilateral hindpaw of sham-
operated rats. Intraplantar URB597 (25g in 50l) did not, however, alter mechanically evoked responses of spinal neurons in spinal
nerve ligated (SNL) rats or hindpaw levels of endocannabinoids. Intraplantar injection of a higher dose of URB597 (100 g in 50 l)
significantly ( p 0.05) attenuated evoked responses of spinal neurons in SNL rats but did not alter hindpaw levels of endocannabinoids.
Spinal administration of URB597 attenuated evoked responses of spinal neurons and elevated levels of endocannabinoids in sham-
operated and SNL rats. These data suggest that peripheral FAAH activitymay be altered or that alternative pathways ofmetabolism have
greater importance in SNL rats.
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Introduction
Recent studies suggest that cannabis-based medicines have ther-
apeutic potential for the treatment of neuropathic pain states
(Hohmann, 2002). Activation of both the cannabinoid 1 receptor
(CB1) and CB2 reduces nociceptive processing in animal models
of neuropathic pain (Hohmann, 2002;Howlett et al., 2002; Elmes
et al., 2004; Sagar et al., 2005). Furthermore, nociceptive process-
ing is tonically modulated by the endocannabinoids. Both CB1
receptor antisense oligonucleotides (Richardson et al., 1998;
Dogrul et al., 2002) and CB1 receptor antagonists facilitate noci-
ceptive responses (Herzberg et al., 1997; Richardson et al., 1997,
1998; Calignano et al., 1998; Strangman et al., 1998; Chapman,
1999).
A novel experimental approach to treating pain is the aug-
mentation of levels of endocannabinoids. Fatty acid amide hy-
drolase (FAAH) is the main enzyme responsible for the metabo-
lism of several endogenous fatty acid amides, including
anandamide (AEA), palmitoylethanolamide, and oleamide
(Deutsch and Chin, 1993; Desarnaud et al., 1995; Maurelli et al.,
1995; Ueda et al., 1995; Cravatt et al., 1996). FAAH inhibitors,
such as cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester
(URB597) and 1-oxo-1[5-(2-pyridyl)-2-yl]-7-phenyl heptane
(OL135), or deletion of the FAAH gene increases levels of anan-
damide in vivo and in vitro (Cravatt et al., 2001; Clement et al.,
2003; Kathuria et al., 2003; Lichtman et al., 2004b; Fegley et al.,
2005; Hohmann et al., 2005; Makara et al., 2005). FAAH-null
mice are hypoalgesic in models of acute and inflammatory pain,
effects that are blocked by a CB1 receptor antagonist (Cravatt et
al., 2001; Lichtman et al., 2004a). In contrast to studies of acute
and inflammatory pain, it is less clear whether elevating levels of
endocannabinoids modulates aberrant pain responses in models
of neuropathic pain. Indeed, thermal hyperalgesia has been
shown to develop in a similar manner in wild-type and FAAH-
nullmice in the chronic constriction injurymodel of neuropathic
pain (Lichtman et al., 2004a). Furthermore, in the partial nerve
ligation model of neuropathic pain, systemic administration of
URB597 did not alter neuropathic pain behavior (Jayamanne et
al., 2006).
The first aim of this study was to determine whether local
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peripheral or spinal inhibition of FAAH modulates nociceptive
responses in neuropathic rats compared with sham-operated rats
and to determine the contribution of the CB1 receptors to these
effects. Endogenous opioids andperipheral opioid receptors have
been implicated in cannabinoid receptor-mediated antinocicep-
tion inmodels of acute pain (Ibrahim et al., 2005). The contribu-
tion of -opioid receptor mechanisms to the analgesic effects of
endocannabinoids is unknown, and therefore, the ability of the
-opioid receptor antagonist naloxone to attenuate the effects of
URB597 has also been investigated. The second part of this study
investigated the mechanism of action of URB597 on nociceptive
responses by determining whether URB597 alters levels of endo-
cannabinoids and related fatty acids in the hindpaw and spinal
cord tissue of neuropathic and sham-operated rats.
Materials andMethods
All experimentswere performed in accordancewith theUnitedKingdom
Home Office Animals (Scientific Procedures) Act of 1986. Experiments
were performed on 143 Sprague Dawley rats (240–300 g), which were
group housed in a light-controlled room with ad libitum access to food
and water. Rats were divided into 26 experimental groups, of which 11
were sham operated, and 15 were spinal nerve ligated (SNL). Electro-
physiological experiments were performed in 17 groups, of which 7 were
sham operated, and 10 were SNL. One neuron was recorded per rat. The
remaining nine groups were used for endocannabinoid measurement.
Spinal nerve ligation. The spinal nerve ligation model of neuropathic
painwas used in this study. Spinal nerves L5–L6were ligated according to
the procedures described by Kim andChung (1992).Male SpragueDaw-
ley rats (110–130 g) were anesthetized using isoflurane (induction, 3%;
maintenance, 1–1.5%; in 33% O2/67% N2O) and placed in a prone po-
sition. A midline incision was made at the L3–S2 level, and the left
paraspinal muscles at L4–S2 level were separated from spinal processes.
Part of the L6 transverse process was removedwith fine rongeurs, and the
L4–L6 nerves were identified. The L5–L6 spinal nerves were isolated and
tightly ligated distal to the dorsal root ganglia and proximal to the sciatic
nerve formation with 6-0 silk. The wound was closed in two layers using
absorbable sutures andwound clips, after complete hemostasis. A similar
procedurewas performed for the sham surgery, except spinal nerveswere
not ligated. After surgery, the sham-operated and SNL rats were group
housed, and their posture and behavior were closely monitored for 48 h.
From postoperative day 2 onwards, behavioral testing was performed to
assess the development of mechanical allodynia up to day 11 after sur-
gery. Rats were placed in Perspex cubicles with wire mesh grid floors and
allowed to acclimatize before behavioral testing. Mechanical sensitivity
of the ipsilateral and contralateral hindpaws was assessed by measuring
the percentage of foot withdrawal in response to normally innocuous
mechanical punctuate stimuli. Stimuli were delivered, frombelow, to the
plantar surface of the foot using a 10 g von Frey hair stimulus. Each trial
consisted of the application of a single von Frey hair 10 times. Trials were
separated by 5min. At 14–18 d after surgery, in vivo electrophysiological
studies were performed, or tissue was collected formeasurement of levels
of endocannabinoids in hindpaw and spinal cord.
Electrophysiology.Methods were similar to those described previously
(Sokal and Chapman, 2001). Rats were anesthetized with isoflurane in-
halation anesthetic (induction, 3%; surgery, 2%; maintenance, 1–1.5%;
in 33% O2/67% N2O), and a tracheal cannula was inserted. Rats were
then placed in a stereotaxic frame tomaintain stability during recordings.
A laminectomy was performed, lumbar vertebrae L1–L3 were located,
and segments L4–L5 of the spinal cordwere exposed using fine rongeurs.
The spinal cord was held rigid by clamps rostral and caudal to the ex-
posed section of spinal cord (L4/5), and a small well was formed with the
surrounding muscle. Core body temperature was maintained at 36.5–
37.5°C throughout the experiment by means of a heating blanket con-
nected to a rectal temperature probe.
Extracellular single-unit recordings of deep (500–1000 m) wide dy-
namic range (WDR) dorsal horn neurons were made with glass-coated
tungstenmicroelectrodes. Electrodeswere lowered vertically through the
cord with a SCAT-01microdrive (Digitimer,Welwyn Garden City, UK),
and depths of recorded neurons from the spinal cord surface were noted.
Receptive fields of neurons covering one or two toeswere identified using
brush, pinch, and heat stimuli. Single-unit activity was amplified and
filtered (Digitimer). Signals were digitized and analyzed using a Cam-
bridge Electronic Design micro1401 interface and Spike 2 data acquisi-
tion software (Cambridge Electronic Design, Cambridge, UK). Re-
sponses of neurons to a train of 16 transcutaneous electrical stimuli (0.5
Hz; 2 ms pulse width) applied to the center of the receptive field were
recorded. All neurons selected were WDR, exhibiting a short-latency
A-fiber-evoked response (0–20ms after stimulus) andA-fiber-evoked
response (20–90 ms after stimulus). These neurons also exhibited
longer-latency C-fiber-evoked responses (90–300ms after stimulus) and
postdischarge responses (300–800 ms after stimulus).
Responses of neurons to punctate mechanical stimulation of the pe-
ripheral receptive field of varying bending force (8, 10, 15, 26, and 60 g)
were characterized. This range of von Frey hairs includes non-noxious
andnoxious stimuli, because the noxious stimulation-induced pawwith-
drawal threshold in awake animals is 15 g (Chaplan et al., 1994). Individ-
ual von Frey hairs were applied to the center of the receptive field for 10 s
in ascending order. Mechanical stimulation of the receptive field was
repeated every 10 min. Once stable control responses (10% variation)
were obtained, pharmacological studies were performed.
Drug treatment. In sham-operated rats, effects of intraplantar injec-
tions of URB597 (25 g in 50 l; n  6; Alexis Biochemicals, Lausen,
Switzerland) or vehicle (50 l of 3% Tween 80 in physiological saline;
n  4) on mechanically evoked responses of WDR neurons were re-
corded for 60 min. Similarly, effects of intraplantar injection of URB597
(25 and 100 g in 50 l; n 6) or vehicle (n 4) were studied in SNL
rats. The contributions of CB1 versus -opioid receptors to the inhibi-
tory effects of URB597 were investigated. In a separate groups of rats, the
effects of intraplantar injection of the CB1 antagonist N-1-(2,4-dichloro-
phenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carbox-
amide (AM251; 30 g in 50 l; n 6; Tocris Bioscience, Bristol, UK) or
the opioid antagonist naloxone (10 g in 50 l of physiological saline;
n  6; Sigma, Poole, UK), 30 min before intraplantar injection of
URB597, on URB597-mediated inhibitions were investigated in sham-
operated and SNL rats for an additional 60min. To ascertain whether the
effects of URB597 were attributable to a local site of action, the effects of
a contralateral injection of URB597 (100 g in 50 l) on ipsilateral
hindpaw stimulation-evoked neuronal responses were studied in a sep-
arate group of SNL rats (n 6).
In separate groups of sham-operated (n  6) and SNL (n  8) rats,
effects of spinal application of URB597 (10, 25, and 50 g in 50 l)
directly onto the exposed spinal cord on mechanically evoked responses
ofWDR neurons were recorded for 50min per dose. The ability of spinal
administration of the CB1 receptor antagonist AM251 (1 g in 50 l) 30
min before URB597 (50g in 50l) or naloxone 10min before URB597
(50g in 50l) to attenuate the inhibitory effect of URB597 onmechan-
ically evoked responses of WDR neurons was also studied in sham-
operated (n  5–6) and SNL rats (n  5–6). The doses of AM251
(Johanek and Simone, 2004; Ibrahim et al., 2005) and naloxone (Dick-
enson and Sullivan, 1986; Johanek and Simone, 2004; Ibrahim et al.,
2005) used were based on previously published literature.
Measurement of endocannabinoids in hindpaw skin and spinal cord.
Separate groups of SNL and sham-operated rats were anesthetized as
described above. URB597 (25 and 100g in 50l; n 6) or vehicle (3%
Tween 80 in saline; n 6)was injected into the ipsilateral hindpawof rats
in a manner identical to that performed for the electrophysiological ex-
periments. Twenty minutes later, the rats were killed, and the ipsilateral
and contralateral hindpaw skin was dissected and stored at 80°C for
measurement of endocannabinoids and related compounds. In separate
groups of SNL and sham-operated rats, URB597 (50 g in 50 l; n 6)
or vehicle (3% Tween 80 in saline; n  4) was applied directly to the
spinal cord. Thirty minutes later, the rats were killed, the ipsilateral and
contralateral spinal cord was dissected, and the tissue was stored at
80°C for 2 to 4 weeks before spectrometric analysis.
A lipid extraction method was used; in brief, tissue was homogenized
in an ethyl acetate/hexanemixture with internal standards added in fixed
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amounts to all samples [0.42 nmol of anandamide-d8, 1.5 nmol of
2-arachidonyl glycerol (2AG)-d8, and 0.2 nmol of heptadecanoyl eth-
anolamide (HEA)], followed by repeated centrifugation and supernatant
collection stages. Anandamide-d8 was used as an internal standard for
AEA, palmitoyl ethanolamide (PEA), oleoyl ethanolamide (OEA), and
virodhamine; 2-arachidonyl glycerol-d8 was used as an internal standard
for 2AG, 2-linoleoylglycerol (2LG), andnoladin ether; andHEAwas used
as internal standard for arachidonyl glycine.
Solid-phase extraction was subsequently performed to purify samples.
Simultaneous measurement of endocannabinoids and related com-
pounds was then performed using liquid chromatography–tandemmass
spectrometry. Analysis was performed on an Agilent (Agilent Technolo-
gies, Waldbronn, Germany) 1100 system coupled to a triple quadrupole
Quattro Ultima MS (Waters, Manchester, UK) recording in
electrospray-positive mode. Analytes were separated chromatographi-
cally on a HyPurity Advance C8 column and precolumn (internal diam-
eter, 100  2.1 mm; particle size, 3 m; Thermo Fisher Scientific,
Rocurn, UK) with a mobile-phase flow rate of 0.3 ml/min. A gradient
elution was used, with mobile phases consisting of A (water, 1 g/L am-
monium acetate, and 0.1% formic acid) and B (acetonitrile, 1 g/L ammo-
nium acetate, and 0.1% formic acid). Samples were injected from a cooled
auto samplermaintainedat 4°C.Multiple-reactionmonitoringof individual
compounds using specific precursor and product mass-to-charge (m/z) ra-
tios allowed simultaneous measurement of AEA, 2AG, PEA, OEA, 2LG,
virodhamine, noladin ether, and arachidonyl glycine. The peak area of each
analyte was divided by the appropriate internal standard peak area, and this
analyte/internal standard ratiowasused to achieve quantitationby the inter-
nal standardmethod. Individual calibration lineswere obtainedduring each
analytical run by applying the method to a suitable range of concentrations
of thenondeuterated formsof eachanalyte.Data is reportedonly foranalytes
above the limit of quantitation by this method [10 pmol/g except for 2AG
(100 pmol/g)]. The method used here has been validated for the measure-
ment of endocannabinoids andwas described in detail previously (Richard-
son et al., 2006).
Data analysis. Control mechanically evoked responses of WDR neu-
rons were the average of three trains of stimulation before vehicle/drug
injection. Properties (control evoked responses and depth) ofWDRneu-
rons before drug/vehicle administration were statistically compared us-
ing t test or one-way ANOVA as appropriate. Comparisons of the effects
of vehicle versus URB597 on evoked activity of WDR neurons after in-
jection into the receptive field were performed with one-way ANOVA.
The time course of effects of drug treatments on evoked responses of
WDR neurons of SNL and sham-operated rats were analyzed using
repeated-measures ANOVA followed by Dunnett’s post hoc test to iden-
tify the time point ofmaximal drug effect (data not shown). For compar-
ison of the maximal effects of vehicle versus drug treatment on neuronal
responses in SNL or sham-operated rats, data were normalized and ex-
pressed as a percentage of the predrug control value. This was performed
to take into account any inherent variation in control evoked responses
before drug treatment between individual rats. Given the size of groups
compared, these data were analyzed with a nonparametric Mann–
Whitney test, and p 0.05was considered significant. Data are expressed
as mean  SEM of percentage of control responses. Endocannabinoid
levels were calculated as the ratio of the area of the endocannabinoid peak
to its internal standard on the spectrogram and are expressed as moles
per gram of wet weight of tissue. Spectrometric data were statistically
compared using aMann–Whitney nonparametric test and are presented
as mean SEM.
Results
Development of mechanical allodynia in SNL rats
After spinal nerve ligation surgery, rats exhibited normal groom-
ing behavior and weight gain similar to the sham-operated con-
trols. The development of mechanical allodynia was assessed for
up to 17 d after surgery. Before electrophysiological studies, rats
exhibited significant mechanical allodynia. On day 11 after sur-
gery, application of a 10 g mechanical stimulus to the ipsilateral
hindpaw of SNL rats evoked a significant increase in paw with-
drawal (58 8% paw withdrawal; p 0.001; mean SEM; n
28) comparedwith sham-operated rats (1 1%pawwithdrawal;
n  22). Similarly, at day 17 after surgery, application of a 10 g
stimulus to the ipsilateral hindpaw of SNL rats produced hind-
paw withdrawal (78 8% paw withdrawal; n 7). In contrast, a
10 g stimulation of the contralateral hindpaw did not evoke a
significant paw withdrawal in SNL or sham-operated rats (data
not shown). Thus SNL rats developed marked mechanical allo-
dynia after tight ligation of L5 and L6 nerves, which is in agree-
ment with previous studies of this model (Kim and Chung, 1992;
Chapman et al., 1998; Elmes et al., 2004; Jhaveri et al., 2005).
Characteristics of neuronal responses of SNL and
sham-operated rats
In vivo single-unit extracellular recordings of dorsal horn neu-
rons were performed between postoperative days 14 and 18 in
SNL and sham-operated anesthetized rats. The mean depths of
WDR neurons (500–1000 m; corresponding to lamina V–VI)
and control electrically evoked A- and C-fiber responses were
similar for the population of neurons recorded from sham-
operated and SNL rats (Table 1). Predrug control mechanically
evoked responses of WDR neurons increased incrementally after
the application of ascending weights of calibrated von Frey
monofilaments (8–60 g) to the center of the receptive field on the
hindpaw. The frequencies of mechanically evoked responses of
WDR neurons in SNL rats were significantly lower than in sham-
operated rats (Fig. 1), which is in keeping with a previous report
(Chapman et al., 1998).
Effects of intraplantar injection of URB597 on responses of
WDR neurons in SNL and sham-operated rats
Insertion of the needle and injection of URB597 or vehicle into
the peripheral receptive field induced firing of WDR neurons,
which often persisted after removal of the needle. The frequency
and duration of firing of WDR neurons immediately after in-
traplantar injection of URB597 (25 g in 50 l per rat) into the
peripheral receptive field was not significantly ( p 0.05) differ-
ent from the effects of vehicle in both sham-operated and SNL
rats (data not shown).
Intraplantar injection of vehicle produced minor increases in
mechanically evoked responses ofWDRneurons, comparedwith
predrug control responses, in both sham-operated and SNL rats.
Although these increases in response were not significant, they
may reflect a small peripheral sensitization after intraplantar in-
jection of vehicle. There were no significant differences between
the effects of intraplantar injection of vehicle on mechanically
evoked responses of WDR neurons in sham-operated and SNL
rats, and therefore these data were pooled for statistical compar-
isons and clarity of presentation. Intraplantar injection of
URB597 (25 g in 50 l) significantly reduced mechanically
evoked responses of WDR neurons in sham-operated rats, with
the exception of the 60-g-evoked response, compared with vehi-
cle (Fig. 2). Maximal inhibitory effects of URB597 were observed
at 20 min after injection. In contrast, intraplantar injection of
URB597 (25 g in 50 l) had no significant effect on mechani-
cally evoked responses of WDR neurons in SNL rats (Fig. 2).
However, intraplantar injection of a higher dose of URB597 (100
g in 50 l) significantly inhibited the mechanically evoked re-
sponses ofWDRneurons in SNL rats. Effects of the higher dose of
URB597 in SNL rats were comparable with the effects of URB597
(25 g in 50 l) in sham-operated rats. Intraplantar injection of
URB597 (100 g in 50 l) in the contralateral paw did not alter
mechanically evoked responses of dorsal horn neurons in SNL
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rats ( p  0.05; Mann–Whitney test; n  6) compared with the
effects of injection of vehicle in ipsilateral paw (mean  SEM;
percentage of control evoked responses after contralateral
URB597: 8 g, 108 16; 10 g, 116 22; 15 g, 102 13; 26 g, 114
16; 60 g, 99 6 vs ipsilateral vehicle: 8 g, 155 38; 10 g, 131 12;
15 g, 109 5; 26 g, 97 4; 60 g, 109 12).
Inhibitory effects of URB597 are attenuated by CB1
receptor blockade
Intraplantar injection of the CB1 receptor antagonist AM251 (30
g in 50l) did not altermechanically evoked responses of spinal
neurons during the 30 min pretreatment period in sham-
operated and SNL rats, except for 8-g-evoked responses in the
former group. AM251 significantly attenuated the inhibitory ef-
fects of URB597 (25 g in 50 l) on mechanically evoked re-
sponses of WDR neurons in sham-operated rats (Fig. 2). Simi-
larly, AM251 also attenuated the inhibitory effects of the higher
dose of URB597 in SNL rats (Fig. 2). These data support the role
of CB1 receptors inmediating the inhibitory effects of URB597 in
both sham-operated and SNL rats.
Differential contributions of-opioid receptors to the
inhibitory effects of URB597 in sham-operated and SNL rats
Previous studies suggest that the inhibitory effects of peripherally
administered cannabinoid agonists may be mediated, at least in
part, by -opioid receptors (Ibrahim et al., 2005). To investigate
whether this interplay with the opioid receptor system extends to
the endocannabinoids, the ability of the-opioid receptor antag-
onist naloxone to attenuate the inhibitory effects of URB597 was
also studied. Intraplantar injection of naloxone (10 g in 50 l)
did not alter mechanically evoked responses of WDR neurons,
comparedwith vehicle, during the 30min pretreatment period in
either sham-operated and SNL rats (Fig. 2). Pretreatment with
naloxone did, however, attenuate the effects of URB597 on me-
chanically evoked responses of WDR neurons in sham-operated
rats but not in SNL rats (Fig. 2).
Effects of spinal administration of URB597 on responses of
WDR neurons in sham-operated and SNL rats
Spinal administration of vehicle (50l of 3% Tween 80 in saline)
at 50 min intervals over a 150 min period did not alter 8- to
60-g-evokedWDRneuronal responses comparedwith prevehicle
controls in SNL rats ( p 0.05; repeated-measures ANOVA; n
5). All statistical comparisonsweremadewith values fromvehicle
control data in SNL rats. Spinal administration of URB597 did
not have significant effects on 8- and 10-g-evoked responses of
WDR neurons in sham-operated and SNL rats, compared with
vehicle controls (data not shown). URB597 (10, 25, and 50 g in
50 l) dose-relatedly inhibited 15-g-evoked responses of WDR
neurons in both sham-operated [percentage control  SEM,
URB597 (10, 25, and 50 g), 123  33, 67  32, and 36  10,
Table 1. Characteristics of dorsal horn neurons in the different treatment groups
n Depth (M)
Evoked responses (Hz)
A A C PD
Sham rats
Intraplantar
Vehicle 4 815 51 203 19 268 56 622 100 635 188
URB (25g) 6 912 28 178 24 179 38 418 74 349 99
AM251 plus URB (25g) 6 698 64 143 18 162 34 514 71 637 106
Nal plus URB (25g) 6 692 61 156 16 177 18 431 58 428 83
Spinal
URB (10, 25, and 50g) 6 820 40 163 29 176 29 585 140 363 120
AM251 plus URB (50g) 6 744 70 113 10 145 40 522 82 492 130
Nal plus URB (50g) 5 730 56 136 9 149 10 547 46 519 152
SNL rats
Intraplantar
Vehicle 4 760 138 167 14 167 8 365 68 245 50
URB (25g) 6 723 87 142 21 151 20 372 57 333 72
URB (100g) 6 755 54 150 12 219 29 580 73 722 112
AM251 plus URB (100g) 6 712 54 159 9 184 25 439 68 434 124
Nal plus URB (100g) 6 718 64 153 12 148 13 327 27 307 75
URB (100g) contralateral paw 6 682 48 147 7 105 16 274 35 292 36
Spinal
Vehicle 5 610 46 152 11 177 34 439 119 385 135
URB (10, 25, 50g) 8 666 38 88 8.4 132 24 484 77 554 99
AM251 plus URB (50g) 5 854 168 102 14 147 20 598 99 647 49
Nal plus URB (50g) 6 852 73 102 20 160 13 417 30 509 84
Depths from the surface of the spinal cord and electrically (A, A-fiber; A, A-fiber; C, C-fiber; PD, postdischarge) evoked responses of neurons were statistically compared using one-way ANOVAwith their respective controls. Data are
expressed as mean SEM. n, Number of neurons per group; URB, URB597; Nal, naloxone.
Figure 1. Control mechanically evoked responses of dorsal horn wide dynamic range neu-
rons in sham-operated and SNL rats. Datawere analyzed using aMann–Whitney nonparamet-
ric test. *p 0.05 and **p 0.01 versus sham. Data are expressed as mean SEM (n
39–58 neurons per group).
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respectively] and SNL rats [percentage control SEM, URB597
(10, 25, and 50g), 77 46, 87 62, and 55 40, respectively].
Effects of spinal URB597 on 26- and 60-g-evoked responses of
WDR neurons are presented in Figure 3. The lowest dose of
URB597 studied (10 g in 50 l) significantly ( p 0.05) inhib-
ited 15- and 60-g-evoked responses ofWDRneurons in SNL rats,
compared with time-matched vehicle controls, but not in sham-
operated rats. URB597 (25 g in 50 l) significantly ( p 0.05)
inhibited 26- and 60-g-evoked responses of WDR neurons in
SNL rats, compared with time-matched vehicle controls.
URB597 (25 g in 50 l) only significantly ( p 0.05) inhibited
60-g-evoked responses in sham-operated rats. The highest dose
of URB597 studied significantly ( p  0.05) inhibited 15- to 60-
g-evoked responses in both sham-operated and SNL rats, com-
pared with time-matched vehicle controls.
The contribution of spinal CB1 receptors to the effects of spi-
nal URB597 was investigated in sham-operated and SNL rats.
Spinal preadministration of the CB1 receptor antagonist AM251
(1 g in 50 l) alone had no significant effect on 10-, 15-, and
60-g-evoked responses of WDR neurons in sham-operated or
SNL rats. AM251 did, however, significantly increase 8- and 26-
g-evoked responses of WDR neurons in SNL rats compared with
time-matched vehicle controls (8 g, p  0.02; 26 g, p  0.02;
Mann–Whitney test; n 5). Spinal preadministration of AM251
(1g in 50l) significantly attenuated the effects of URB597 (50
g in 50 l) on 15- to 60-g-evoked responses in sham-operated
Figure 2. A, B, Intraplantar injection of a low dose of URB597 (URB) reduced mechanically
evoked responses of wide dynamic range neurons in sham-operated (A) but not SNL (B) rats. A
higher dose of URB attenuated evoked responses in SNL rats. Inhibitory effects of URB were
attenuated by AM251 (30g) in both sham-operated and SNL rats. Inhibitory effects of URB
were also attenuated by naloxone (Nal; 10g) in sham-operated rats. All drugs were given in
a volume of 50l. Data were statistically analyzed with a nonparametric Mann–Whitney test.
Effects of vehicle in sham-operated and SNL rats did not differ significantly and were pooled
(n 8). *p 0.05, **p 0.01, and ***p 0.001 versus vehicle. #p 0.05 and ##p 0.01
versus URB (25g)–sham. #p 0.05 and ##p 0.01 versus URB (100g)–SNL. Data are
expressed as mean SEM (n 6–8 neurons per group).
Figure3. A,B, SpinaladministrationofURB597(URB;10,25,and50g)dose-relatedly reduced
26- and 60-g-evoked responses of WDR neurons in sham-operated (A) and SNL (B) rats. Effects of
URB597wereblockedbyspinalpreadministrationofAM251(1g).Alldrugsweregiven inavolume
of 50l. Data were statistically compared using a Mann–Whitney nonparametric test and are ex-
pressed as mean SEM (n 5–8 neurons per group). *p 0.05 and **p 0.01 versus time-
matched vehicle control. #p 0.05 and ##p 0.01 versus URB (50g).
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rats and 26- to 60-g-evoked responses in SNL rats (Fig. 3; for
clarity of presentation, 15 g data are not presented).
The role of spinal opioid receptors in mediating the effects of
spinally administered URB597 (50 g in 15 l) was also investi-
gated. Preadministration of spinal naloxone (15 g in 50 l)
attenuated the inhibitory effects of URB597 in both sham-
operated and SNL rats to a similar extent. Naloxone significantly
(mean SEM; percentage of control: 15 g, 85 15; 26 g, 79 11;
60 g, 92 9; p 0.05;Mann–Whitney test; n 5–6) blocked the
effects of URB597 (15 g, 36 10; 26 g, 37 10; 60 g, 29 6) on
mechanically evoked responses of dorsal horn neurons in sham-
operated rats. Naloxone also significantly ( p  0.05; Mann–
Whitney test; n  6) blocked the effects of URB597 in SNL rats
(mean  SEM; percentage of control, naloxone plus URB597:
15 g, 91 11; 26 g, 97 11; 60 g, 88 14
vs URB597 alone: 15 g, 14 5; 26 g, 27
6; 60 g, 34  6). Naloxone alone did not
alter mechanically evoked responses of
spinal neurons, compared with time-
matched vehicle controls (data not
shown).
Effects of intraplantar injection of
URB597 on levels of endocannabinoids
In separate experiments, the effects of in-
traplantar injection of URB597 (25 g in
50 l), versus vehicle, on levels of endo-
cannabinoids in the hindpaw were mea-
sured in sham-operated and SNL rats and
compared with corresponding synthetic
standards (Fig. 4). In sham-operated rats,
intraplantar injection of vehicle had no
significant effects on the levels of AEA,
OEA, 2AG, or PEA in the ipsilateral hind-
paw, compared with the contralateral paw
(Fig. 5). Comparison of the effects of in-
traplantar injection of vehicle in SNL rats
on levels of endocannabinoids and related
fatty acids in the ipsilateral hindpaw re-
vealed that injection of vehicle increased
levels of AEA ( p  0.05) and OEA (not
significant), compared with the contralat-
eral paw of SNL rats (Fig. 5). Levels of AEA
and OEA in the ipsilateral paw of vehicle-
treated SNL rats were also higher than in
the vehicle-treated hindpaw of sham-
operated rats. In contrast, intraplantar in-
jection of vehicle did not significantly alter
levels of 2AG in the ipsilateral hindpaw of
SNL or sham-operated rats. Effects of ve-
hicle treatment on levels of PEA and 2LG
were more complex and did not follow a
similar profile.
Twenty minutes after intraplantar in-
jection of URB597 (25 g in 50 l) in
sham-operated rats, levels of AEA, 2AG,
and OEA were significantly increased in
the ipsilateral hindpaw, compared with
the contralateral hindpaw (Fig. 5). In-
creases in the levels of 2AG andOEA in the
URB597-treated ipsilateral hindpaw of
sham-operated rats were statistically sig-
nificant compared with the effects of vehi-
cle (Fig. 5). Thus, on the basis of the changes in levels of endo-
cannabinoids and related fatty acids after intraplantar injection
of URB597, we can conclude that the lower dose of URB597
produces inhibitory effects on neuronal responses in parallel with
increased levels of endocannabinoids and related fatty acids in
sham-operated rats. In contrast to sham-operated rats, intraplan-
tar injection of URB597 (25 g in 50 l) did not alter levels of
AEA, 2AG, OEA, PEA, and 2LG in the ipsilateral hindpaw of SNL
rats, compared with contralateral hindpaw. Because in the elec-
trophysiological studies a higher dose of URB597 (100 g in 50
l) attenuated mechanically evoked responses of dorsal horn
neurons in SNL rats, the ability of this dose of URB597 to mod-
ulate levels of endocannabinoids and related fatty acids in the
hindpaw was also investigated. Intraplantar injection of a higher
Figure 4. a–m, Representative chromatograms of native endocannabinoids and related fatty acids detected in rat paw tissue
(a, d, h, j, l ), along with the corresponding synthetic standards used to construct calibration curves (b, e, i, k,m) and the three
internal standards, AEA-d8, 2AG-d8, andHEA (note differences inm/z values) used to quantify levels of these compounds (c, f,g).
The additional peak inb correspondswith the virodhamine standard,which shares the precursor andproductm/z valueswithAEA
and is therefore solely differentiated by chromatographic separation.
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dose of URB597 (100 g in 50 l) in SNL
rats decreased levels of AEA, 2AG, OEA,
and PEA in the ipsilateral hindpaw, com-
pared with the contralateral hindpaw; sig-
nificance was only reached for OEA and
PEA (Fig. 5). Both the low and high dose of
URB597 decreased levels of AEA and OEA
in the ipsilateral hindpaw compared with
vehicle treatment in SNL rats. It is impor-
tant to note, however, that levels of AEA
and OEA were significantly higher in the
ipsilateral hindpaw of vehicle-treated SNL
rats compared with vehicle-treated sham-
operated rats. These data indicate that
there is a greater sensitivity of sham-
operated rats to the effects of URB597 and
that in SNL rats, endocannabinoids and
related fatty acids are not elevated by
URB597, suggesting that they are metabo-
lized by alternative pathways.
Effects of spinal administration of
URB597 on levels of endocannabinoids
The effects of spinal administration of
URB597 (50g in 50l) versus vehicle on
levels of endocannabinoids and related
fatty acids was investigated in SNL and
sham-operated rats. URB597 significantly
( p  0.05) increased levels of AEA and
2AG in the ipsilateral spinal cord of SNL
rats, compared with vehicle treatment in
SNL rats (Fig. 6). In contrast, URB597 did
not alter levels of AEA in the ipsilateral or
contralateral spinal cord of sham-operated
rats compared with vehicle treatment (Fig.
5). URB597 did, however, significantly
( p  0.05) increase levels of 2AG in the
ipsilateral and contralateral spinal cord of
sham-operated rats comparedwith vehicle
treatment (Fig. 6). URB597 significantly
( p  0.05) increased the levels of PEA in
the ipsilateral spinal cord, compared with
vehicle treatment in SNL rats, but had no
significant effect on levels of PEA in sham-
operated rats (data not shown). Spinal lev-
els of OEA and 2LG were not altered by
spinal administration of URB597 in SNL
or sham-operated rats (data not shown).
Discussion
Intraplantar injection of URB597 elevated
levels of AEA, OEA, and 2AG in the ipsi-
lateral hindpaw and significantly reduced
mechanically evoked responses of dorsal
horn neurons in sham-operated rats. In-
hibitory effects were attenuated by
AM251, suggesting that elevated levels of
AEA and 2AG act via CB1 receptors to pro-
duce their functional effects. In contrast, in neuropathic rats, the
same intraplantar dose of URB597 had no effect, although a
higher dose attenuated responses of spinal neurons in neuro-
pathic rats, without increasing levels of endocannabinoids in the
ipsilateral hindpaw.
Metabolism of endocannabinoids and related fatty acid
amides plays a major role in limiting their biological effects. Al-
though FAAH is the predominant enzyme responsible for the
metabolism of AEA, OEA, and PEA in the brain (Fegley et al.,
2005), the contribution of different metabolic pathways (Mulder
and Cravatt, 2006) in peripheral tissue or under conditions of
Figure 5. a–e, Effects of intraplantar injection of URB597 (URB; 25 or 100g in 50l) on the levels of endocannabinoids (a,
c) and related fatty acids (b, d, e) in the ipsilateral (filled bars) and contralateral (open bars) hindpaw of sham-operated and SNL
rats. Data were analyzed using a Mann–Whitney nonparametric test and are expressed as mean SEM picomoles per gram (a)
or nanomoles per gram (b–e) (n 6 rats per group). *p 0.05 and **p 0.01 versus contralateral paw; p 0.05 and
p 0.01 versus ipsilateral vehicle (Veh)–sham; ƒp 0.05 and ƒƒp 0.01 versus ipsilateral vehicle–SNL.
Figure 6. Effects of spinal administration of URB597 (URB; 50g in 50l) on the levels of endocannabinoids in the ipsilateral
(filled bars) and contralateral (open bars) spinal cord of sham-operated and SNL rats. a, b, Data were analyzed using a Mann–
Whitneynonparametric test andare expressedasmean SEMpicomoles per gram(a) or nanomoles per gram(b) (n4–6 rats
per group). p 0.01 versus ipsilateral vehicle (Veh)–sham; ƒp 0.05 and ƒƒp 0.01 versus ipsilateral vehicle–SNL.
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pathology is unclear. Increased FAAH activity or changes in pH
(Paylor et al., 2006) in the hindpaw of neuropathic rats could
account for the reduced potency ofURB597. Alternative routes of
endocannabinoid metabolism, such as cyclooxygenase-2
(COX-2) (Kozak et al., 2004), may also be engaged in peripheral
tissue in neuropathic pain states and contribute to endocannabi-
noid metabolism in the presence of FAAH inhibition. Indeed,
increased COX-2 metabolism of AEA has been reported in
FAAH-null mice (Weber et al., 2004). The inhibitory effects of
the higher dose of URB597 in neuropathic rats were sensitive to a
CB1 receptor antagonist but were not associated with elevated
levels of AEA or 2AG, indicating that, in the presence of FAAH
inhibition, endocannabinoids are metabolized by alternative
pathways tometabolites that modulate nociceptive processing or
nonselective effects of this dose of URB597.
The peripheral effects of URB597 in sham-operated rats were
mirrored by inhibitory effects of spinal URB597 in sham-
operated rats, corroborating previous reports that FAAH inhibi-
tors are antinociceptive in models of acute and inflammatory
pain (Cravatt et al., 2001; Kathuria et al., 2003; Lichtman et al.,
2004a,b; Holt et al., 2005; Jayamanne et al., 2006). Intrathecal
URB597 increased levels of 2AG, but not AEA or PEA, in the
ipsilateral spinal cord of sham-operated rats. Spinal administra-
tion of URB597 attenuated evoked responses of neurons in neu-
ropathic rats and significantly increased levels of AEA, PEA, and
2AG in the ipsilateral spinal cord. Previously, it has been shown
that a single dose of systemic URB597 does not alter neuropathic
pain behavior (Jayamanne et al., 2006), whereas the FAAH inhib-
itorOL135 attenuated allodynia in neuropathic rats (Chang et al.,
2006). Our data suggest that there may be tissue-specific changes
in the sensitivity to URB597 in neuropathic rats, whichmay arise
as a result of changes in FAAH activity, metabolic pathways, and
tissue pH (Paylor et al., 2006).
Inhibitory effects of peripheral and spinalURB597 in SNL and
sham-operated rats were blocked by AM251, demonstrating the
contribution of CB1 receptors. CB1 receptor-mediated antinoci-
ception has been widely described in neuropathic rats (Herzberg
et al., 1997; Mao et al., 2000; Bridges et al., 2001; Fox et al., 2001;
Monhemius et al., 2001; Helyes et al., 2003; Lim et al., 2003; Scott
et al., 2004; Pascual et al., 2005; Sagar et al., 2005). Our data are
consistent with reports that CB1 receptors mediate the inhibitory
effects of FAAH inhibitors (Cravatt et al., 2001; Kathuria et al.,
2003; Lichtman et al., 2004a,b; Wilson et al., 2004; Hohmann et
al., 2005; Jayamanne et al., 2006). URB597 has been shown to
produce a rapid and sustained (6 h) inhibition of FAAHactivity
in the brain and to increase levels of AEA and other related fatty
acids (Kathuria et al., 2003; Fegley et al., 2005; Hohmann et al.,
2005; Makara et al., 2005). URB597 does not bind to CB1 or CB2
receptors (Kathuria et al., 2003), suggesting that the effects of
URB597 on evoked responses of spinal neurons arise as a result of
CB1 receptor activation by the increased levels of AEA and 2AG in
the ipsilateral hindpaw and spinal cord reported herein.
Inhibitory effects of peripherally and spinally administered
URB597 in sham-operated rats were attenuated by the opioid
antagonist naloxone, supporting evidence for interactions be-
tween the endocannabinoid and opioid receptor systems (Mal-
donado andValverde, 2003; Ibrahim et al., 2005). In SNL rats, the
inhibitory effects of the higher dose of intraplantar URB597 were
not altered by naloxone. Inhibitory effects of spinal URB597,
however, were significantly attenuated by naloxone in SNL rats. It
has been reported recently that inhibitory effects of OL135 are
also blocked by naloxone in SNL rats (Chang et al., 2006). Thus,
it appears that opioid receptors contribute to cannabinoid-
mediated analgesia in neuropathic pain states in a tissue-specific
manner.
Amajor benefit of our analytical approach is the simultaneous
measurement of endocannabinoids and related fatty acids. In
sham-operated rats, inhibitory effects of intraplantar URB597 on
nociceptive responses occurred in parallel with increased hind-
paw levels of AEA, 2AG, and OEA. In contrast, levels of PEA and
2LG were not altered by intraplantar administration of URB597.
FAAH is themain enzyme responsible for themetabolism of PEA
in the brain. Previously, levels of PEAwere shown to be increased
in the duodenum of FAAH knock-out mice, but URB597 did not
alter PEA levels in wild-type or FAAH knock-out mice, suggest-
ing that additional pathways metabolize PEA in the periphery
(Fegley et al., 2005). Indeed, an acid amidase enzyme is reported
to be also responsible for the metabolism of PEA in peripheral
tissue and macrophages (Ueda et al., 1999, 2001; Tsuboi et al.,
2004; Sun et al., 2005). PEA is the preferred substrate for
N-acylethanolamine-hydrolyzing acid amidase, which is insensi-
tive toURB597 (Sun et al., 2005). The lack of effect of URB597 on
levels of PEA in hindpaw suggests that N-acylethanolamine-
hydrolyzing acid amidase may play a role in the metabolism of
PEA in the hindpaw, as has been described for other peripheral
tissue.
Another important observation of the present study was that
levels of 2AG in the hindpaw and spinal cord were elevated by
URB597. 2AG has been shown to be metabolized by monoacylg-
lycerol (MAG) lipase (Goparaju et al., 1999; Dinh et al., 2002;
Saario et al., 2004) and FAAH in cell preparations (Cravatt et al.,
1996; Bisogno et al., 1997; Goparaju et al., 1998, 1999; Ueda et al.,
1998, 2002; Lang et al., 1999; Fowler et al., 2001). Our data using
local administration of URB597 in vivo are in agreement with in
vivo studies demonstrating that intraperiaqueductal gray injec-
tion of URB597 increases levels of AEA and 2AG (Maione et al.,
2006) and that intraperitoneal injection of the FAAH inhibitor
N-arachidonyl-serotonin increases levels of 2AG in the brain (de
Lago et al., 2005). In contrast, systemic administration of
URB597 does not increase levels of 2AG (Kathuria et al., 2003;
Fegley et al., 2005), and levels of 2AG are not altered in FAAH
knock-outmice (Fegley et al., 2005). BecauseURB597 is reported
to have no inhibitory effects onMAG lipase (Kathuria et al., 2003;
Lichtman et al., 2004b; Hohmann et al., 2005; Makara et al.,
2005), the present results suggest that 2AG may be metabolized
by FAAH in vivo. Alternatively, the increases in 2AG after admin-
istration ofURB597may arise because of indirect circuit effects of
FAAH inhibition on the production and metabolism of 2AG.
An important consideration when using FAAH inhibitors is
that some endocannabinoids, such as AEA, are also agonists
(Zygmunt et al., 1999; Smart and Jerman, 2000; Smart et al.,
2000) at pronociceptive transient receptor potential vanilloid
subfamily member 1 (TRPV1) receptors, which are upregulated
in primary afferent fibers in neuropathic rats (Macdonald et al.,
2001; Fukuoka et al., 2002; Rashid et al., 2003a,b). In the present
study, levels of AEA and OEA, but not 2AG, were increased after
injection of vehicle in the hindpaw of neuropathic but not sham-
operated rats. The increased tissue content of endocannabinoid
may reflect either increased synthesis or reduced metabolism in
the neuropathic rats, but, given the attenuated response to
URB597 in the neuropathic rats, the latter seems unlikely. The
mechanism responsible for increased levels of AEA and OEA in
response to vehicle injection in neuropathic rats is unknown,
although one possibility is an upregulation of TRPV1 receptor,
which has been suggested to act as an integrator and amplifier of
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calcium-mobilizing signals via intracellular AEA synthesis (van
der Stelt et al., 2005).
In conclusion, peripheral and spinal administration of
URB597 increased levels of AEA, 2AG, and OEA in the hindpaw
and reduced nociceptive processing in sham-operated rats in a
CB1 receptor-dependent manner. The requirement for a higher
intraplantar dose of URB597 in neuropathic rats to attenuate
nociceptive responses suggests that the contribution of FAAH to
endocannabinoid metabolism is altered in neuropathy. These
changes do not appear to be global, because spinal inhibition of
FAAH was equally effective in sham-operated and neuropathic
rats and was associated with increased levels of AEA, PEA, and
2AG.
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